Compositions comprising bacterial strains
Assignee4D Pharma Research Limited
InventorsGeorge Grant, Angela Margaret Patterson, Imke Mulder, Seanin McCluskey, Emma Raftis
Life of this patent
Estimating the term…
Abstract
The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
Claims19
A method of reducing inflammation caused by Th17 differentiation in a subject, comprising orally administering to the subject a pharmaceutical composition that comprises
- a therapeutically effective amount of a bacteria strain of genus Bifidobacterium;
- wherein the Bifidobacterium bacteria strain is lyophilized;
- wherein the Bifidobacterium bacteria strain is positive for fermentation of raffinose as determined by an Analytical Profile Index test comprising:
- (a) contacting a suspension of the Bifidobacterium bacteria strain with a Rapid ID 32A strip at 37° C. for at least 4 hours;
- (b) contacting the suspension with a development reagent comprising FastBlue for at least 5 minutes;
- and
- (c) measuring a color of the suspension;
- wherein the therapeutically effective amount comprises from about 1×106 to about 1×1011 CFU/g of the Bifidobacterium bacteria strain with respect to a total weight of the pharmaceutical composition;
- and
- wherein the administering of the therapeutically effective amount of the Bifidobacteriumbacteria strain results in a reduction of inflammation caused by Th17 differentiation.
A method of reducing inflammation caused by Th17 differentiation in a subject, comprising orally administering to the subject a pharmaceutical composition that comprises
- a therapeutically effective amount of a bacteria strain of species Bifidobacterium breve, wherein the Bifidobacterium breve bacteria strain is lyophilized;
- wherein the Bifidobacterium breve bacteria strain is positive for fermentation of raffinose as determined by an Analytical Profile Index test comprising:
- (a) contacting a suspension of the Bifidobacterium breve bacteria strain with a Rapid ID 32A strip at 37° C. for at least 4 hours;
- (b) contacting the suspension with a development reagent comprising FastBlue for at least 5 minutes;
- and
- (c) measuring a color of the suspension;
- wherein the therapeutically effective amount comprises from about 1×106 to about 1×1011 CFU/g of the Bifidobacterium breve bacteria strain with respect to a total weight of the pharmaceutical composition;
- and wherein the administering of the therapeutically effective amount of the Bifidobacterium breve bacteria strain results in a reduction of inflammation caused by Th17 differentiation.
A pharmaceutical composition, in the form of a tablet, capsule, or microcapsule, that comprises:
- a therapeutically effective amount of a bacteria strain of genus Bifidobacterium;
- and
- a pharmaceutically acceptable excipient, diluent, or carrier;
- wherein the Bifidobacterium bacteria strain is lyophilized;
- wherein the Bifidobacterium bacteria strain is positive for fermentation of raffinose as determined by an Analytical Profile Index test comprising:
- (a) contacting a suspension of the Bifidobacterium bacteria strain with a Rapid ID 32A strip at 37° C. for at least 4 hours;
- (b) contacting the suspension with a development reagent comprising FastBlue for at least 5 minutes;
- and
- (c) measuring a color of the suspension;
- and
- wherein the therapeutically effective amount comprises from about 1×106 to about 1×1011 CFU/g of the Bifidobacterium bacteria strain with respect to a total weight of the pharmaceutical composition and is sufficient to reduce inflammation caused by Th17 differentiation when administered to a subject.
Dependencies are inferred from the claim text.